Health-care companies rose sharply after Moderna earnings.
Shares of Indivior rallied after the company swung to a profit in the fourth quarter and said it is mulling a U.S. primary listing. On Thursday, Moderna reported fourth-quarter revenue slumped to $2.8 billion from $5.1 billion the year before as fewer people got its Covid-19 shot. The company expects its overall respiratory franchise to take in $4 billion in revenue this year, a far cry from the $19.3 billion it generated in 2022.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
02-22-24 1754ET
